Hyperlipidemia — Statin Therapy, LDL Targets & ASCVD Risk

Creator: Progress Note
Published: 2026-07-22
Keywords: statin therapy cardiovascular risk, LDL cholesterol target USMLE, statin side effects rhabdomyolysis, familial hypercholesterolemia, PCSK9 inhibitors ezetimibe

The 60-second version

4 statin benefit groups: clinical ASCVD, LDL ≥190, DM+40–75, 10-yr risk ≥7.5%
High-intensity statins: atorvastatin 40–80mg, rosuvastatin 20–40mg
Statin + gemfibrozil = highest rhabdomyolysis risk; fenofibrate is safer combination
PCSK9 inhibitors (evolocumab, alirocumab): add for ASCVD + LDL >70 on max statin + ezetimibe
Statins contraindicated in pregnancy (teratogenic); DM risk is slight and outweighed by CV benefit

Lipid Metabolism and Causes of Hyperlipidemia

LDL (low-density lipoprotein): primary atherogenic particle. Synthesized in liver from VLDL. Normal <100 mg/dL; high >160; goal <70 for very high risk. HDL: 'reverse cholesterol transport' — takes cholesterol from tissues to liver. Protective; goal >40 (men), >50 (women). Triglycerides: >150 borderline high; >500 = risk of pancreatitis. Secondary causes of dyslipidemia (USMLE favorites): Hypothyroidism (↑LDL — check TSH in all new dyslipidemia). Nephrotic syndrome (↑LDL, ↑TG — hypoalbuminemia → compensatory liver lipoprotein production). Diabetes (↑TG, ↓HDL, LDL relatively normal but small dense LDL particles). Cushing syndrome, alcohol (↑TG). Familial hypercholesterolemia (FH): AD mutation in LDL receptor → LDL 200–400+ mg/dL; premature atherosclerosis; xanthomas (tendon — Achilles and extensor tendons); xanthelasmas (periorbital). Homozygous FH: LDL >400–500 → MI in childhood.

Statin Therapy: 4 Benefit Groups

ACC/AHA guidelines identify 4 groups benefiting from statin therapy: (1) Clinical ASCVD (prior MI, stable angina, prior stroke/TIA, PAD) → HIGH-INTENSITY statin (atorvastatin 40–80mg, rosuvastatin 20–40mg). (2) Primary prevention with LDL ≥190 mg/dL (familial hypercholesterolemia) → HIGH-INTENSITY statin. (3) Diabetes age 40–75 with LDL 70–189 mg/dL → MODERATE-intensity statin (atorvastatin 10–40mg, rosuvastatin 5–10mg, simvastatin 20–40mg). (4) Primary prevention without DM, age 40–75, LDL 70–189 mg/dL, 10-year ASCVD risk ≥7.5% → initiate statin therapy discussion. Risk calculator: ACC/AHA Pooled Cohort Equations (uses age, sex, race, BP, cholesterol, DM, smoking status). When to add non-statin therapy: ASCVD patient with LDL ≥70 on maximum statin → add ezetimibe (blocks intestinal cholesterol absorption, lowers LDL ~20%). If still not at goal → add PCSK9 inhibitor (evolocumab/alirocumab — monoclonal antibodies, lowers LDL 50–60%; inject subcutaneously every 2–4 weeks).

Statin Side Effects and Contraindications

Myopathy: myalgias (most common; CK usually normal), myositis (elevated CK + muscle symptoms), rhabdomyolysis (rare but life-threatening — CK >10× ULN + myoglobinuria → AKI). Risk increased by: high-intensity statin, gemfibrozil combination (simvastatin + gemfibrozil especially dangerous — fenofibrate preferred with statins), CYP3A4 inhibitors (clarithromycin, azole antifungals, amiodarone, grapefruit juice), hypothyroidism, renal failure. Management: mild myalgias → try different statin or reduce dose; switch to hydrophilic statin (pravastatin, rosuvastatin — less CYP3A4 metabolism). Stop statin for CK >10× ULN. Hepatotoxicity: mild ALT elevation common (benign); severe hepatotoxicity rare; check baseline LFTs, recheck only if symptomatic. Teratogenic (Category X) — contraindicated in pregnancy and breastfeeding. Diabetes risk: slight (3–10%) increased risk of new-onset T2DM; cardiovascular benefit still far outweighs this risk. Statins do NOT increase dementia risk (multiple large RCTs confirm).

Test yourself

Quick check — 2 questions

1. A 55-year-old man with a history of MI 2 years ago has LDL 95 mg/dL on atorvastatin 80mg. The next appropriate step is:

2. Which statin is safest to prescribe to a patient on clarithromycin for 10 days?

Frequently asked questions

A patient on simvastatin 40mg develops severe myalgias and CK of 12,000 IU/L. What is the next step?

CK >10× ULN with muscle symptoms = rhabdomyolysis — stop the statin immediately. Severe rhabdomyolysis requires IV fluid resuscitation to prevent myoglobin-induced ATN (target urine output 200–300 mL/hr). Monitor creatinine, potassium, and urine myoglobin. If the patient needs continued lipid-lowering, start a different statin at a lower dose after CK normalizes, or consider pravastatin/rosuvastatin (hydrophilic statins with lower myopathy risk). Check for precipitating factors: CYP3A4 inhibitors, gemfibrozil, hypothyroidism, alcohol.

What is the LDL target for a patient with established ASCVD (prior MI) on statin therapy?

For secondary prevention (clinical ASCVD: prior MI, stable angina, stroke/TIA, PAD), the ACC/AHA guidelines recommend high-intensity statin therapy with an LDL goal of <70 mg/dL. For very high-risk patients (multiple ASCVD events or ASCVD plus risk-enhancing factors), some guidelines suggest LDL <55 mg/dL. If LDL remains ≥70 mg/dL on maximum tolerated statin, add ezetimibe. If still not at goal, add a PCSK9 inhibitor (evolocumab or alirocumab). The 'treat to target' approach (vs. the 'fire and forget' fixed-dose approach) is now favored by ESC/EAS and many practitioners.

Practice makes permanent

Lock this into long-term memory

Progress Note's adaptive engine spaces your reviews automatically — so this stays with you through boards and onto the wards.

Start practicing free

Share Post LinkedIn Reddit

Continue the curriculum

Acute Coronary Syndrome: STEMI, NSTEMI, and Unstable Angina

Type 1 vs Type 2 Diabetes

Atrial Fibrillation: Rate vs Rhythm Control and Anticoagulation